Emerging therapies such as sodium–glucose co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists, and mineralocorticoid receptor antagonists have demonstrated beneficial effects on cardiac structure and function in patients with established HF,21, 22, 23, 24 suggesting they may also hold the potential to favourably influence cardiac function trajectories. The gene discussed is NR3C2; the disease is hydrops fetalis.